RBC Capital Reiterates Outperform on 4D Molecular Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a $40 price target.
July 22, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Luca Issi has reiterated an Outperform rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a $40 price target.
The reiteration of an Outperform rating and the maintenance of a $40 price target by RBC Capital is a positive signal for investors. It suggests confidence in the company's future performance and could lead to increased investor interest and buying activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100